the IDWP section. The definitions are presented in two parts: -one for the different clinical entities which are usually observed. Most of these entities are intended for entering infectious complications in the EBMT data base.
The EBMT Aplastic Anaemia registry contains data of 6086 treatments (as of October 2001). Diagnosis were acquired aplastic anaemia (AA) in 85.8%, Fanconi Anaemia in 9.7%, other constitutional anaemias in 1.2%, pure red cell aplasia in 1% and PNH in 2.3% of cases. In patients with acquired AA etiology was considered idiopathic in 83.3%, post-hepatitis in 8.6%, druginduced in 6.1%, and toxic in 1.2% of cases. Most patients with acquired AA reported to the registry received allogeneic stem cell transplantation (SCT)(n=2894; 57.2%) or immunosuppressive treatment (IS) (n=2153, 42.8%) with or without hematopoietic growth factors. 81.2% of the patients were grafted from an HLAidentical sibling donor, 2.4% from an identical twin, 3.0% from a matched family donor, 4.4% from a mismatched family donor, 7.3% from a matched unrelated donor and 1.7% from a mismatched unrelated donor. The proportion of SCT from alternative donors increased from 13.5% in the era before 1995 to 23.4% since 1995. Since 1994 the number of allogenic PBSCTS for AA is steadily increasing (33.3% and 34.4% of HLA-id. sib. SCTs in 1999 and 2000, resp) . However, careful evaluation of the impact of stem cell source on outcome after transplantation for AA is required. Probability of survival after both allogeneic SCT and IS increased substantially over time. Probability of survival at 5 years after HLA-id. sibl. transplant was 0.39, 0.60, 0.63, 0.74 and 0.72 in the periods before 1981, 1981-1985, 1986-1990, 1991-1995 and since 1996. In the same time periods probability of 5 year survival after IS was 0.47, 0.57, 0.65, 0.76 and 0.75. Factors leading to improved survival include omission of radiation from conditioning regimens, improved GvHD prophylaxis, introduction of multimodal IS and improved supportive treatment. The role of growth factors as a n adjunct to IS for AA is still unclear. Despite the overall improvement in outcome, survival of patients grafted from alternative donors is still significantly lower compared to HLA-identical sib. SCT. Survival at 3 years in patients grafted since 1995 is 0.75 for HLA-identical sibling SCT and 0.65, 0.56 and 0.23 for patients grafted from matched related, matched unrelated and mismatched unrelated donors. Thus, new trials in the SCT field should focus on evaluation of new regimens for alternative donor transplantation. For patients not eligible for allogeneic SCT the role of growth factors and new immunosuppressive drugs should be evaluated.
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Fludarabine, cyclophosphamide and ATG for alternative donor transplants in aplastic anemia -A report of the SAA Working Party A. Bacigalupo, F. Locatelli, G. Socié, G. Dini, A. Pession, A. Locasciulli, A. Prete, H. Schrezenmeier (Genoa, Pavia, I; Paris, F; Bologna, Rome, I; Berlin, D) Fifteen patients with severe aplastic anemia underwent an alternative donor transplant following a conditioning regimen without radiation: patients received fludarabine 30 mg/m^2 + cyclophosphamide 300 mg/m^2x4 +antithymocyte globulin (Thymoglobulin) 3.75 mg/kg on days-5-4-3-2 before transplant. The etiology was idiopathic in 8 and constitutional in 7 (Fanconi) . The donor was an unrelated donor in 10 or a family member in 5 (1 was a phenotypic matched father, 3 were one antigen mismatched relatives and one was 3 antigens mismatched). The source of stem cells was unmanipulated bone marrow in 14, and CD34+ selected PB cells in one. Graft versus host disease prophylaxis consisted of cyclosporin 1 mg/kg from day -7 to day +20 and methotrexate 10 mg/m^2 on days +1, +3, +6,+11 after transplant. All patients engrafted with a median level of donor chimerism of 100% within day +100 and 100% beyond day +100. One patient showed graft failure and died after conventional transplant of GvHD. Thirteen patients (86%) had grade 0-I acute GvHD , one had grade II and one grade III GvHD. Five patients (33%) developed chronic GvHD. At a median follow up interval of 286 days (range 71-1334) 11/15 (73%) patients survive with graft function. Survival was 75% and 71% respectively in acquired and Fanconi anemia. This study confirms that an immunosuppressive conditioning regimen is sufficient to engraft young patients with aplastic anemia, using unmanipulated bone marrow and CyA+MTX as GvHD prophylaxis.
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Allogeneic stem cell transplantation for adult chronic myelomonocytic leukaemia -A report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)
N. Kröger, T. Zabelina, P. Guardiola, V. Runde, J. Sierra, A. van Biezen, D. Niederwieser, A. Zander, T. 
de Witte for the Chronic Leukaemia Working Party
Chronic myelomonocytic leukaemia (CMML) is a rare hematological neoplastic disease, characterised by increased monocytic cells in the bone marrow and peripheral blood. Because of dysplastic features, CMML was classified as a subtype of myelodysplastic syndromes (MDS) by the FAB group in 1982. We report the results of 50 allogeneic transplantations performed between 12/1988 and 1/2000 in 43 European centers in 32 male and 25 female with CMML. The median age at transplant was 44 years (range 19-63), and the median time from diagnosis to transplant was 9 months (range 1-57). 18 patients had excess blasts ranging from 5% to 30% at time of transplantation. Cytogenetic data was available in 34 pts, showing abnormal karyotype in 13 cases (mainly monosomy 7). Donors were HLA identical siblings in 38 cases, HLA matched unrelated in 6 cases, HLA mismatched related in 5 cases, and HLA matched other related in one cases. Two graft failures were observed (4%). Neutrophil engraftment (>500/mm³) and platelet engraftment (>50000/mm³) was reached after a median of 17 days (range 11-50) and 29 days (range 11-268), respectively. 26% experienced acute GvHD grade II-IV, while 18% developed severe aGvHD
